This Bivigam market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historical period can be attributed to several factors, including the increasing prevalence of immune deficiency disorders, a rise in global healthcare spending, better access to life-saving treatments, greater awareness of immune deficiency disorders, regulatory approvals, and advancements in therapy guidelines.
Growth during the market's forecast period is expected to be driven by rising healthcare expenditure, growing demand for innovative immune therapies, expanded healthcare access in emerging markets, government and private funding for rare disease treatments, and an increasing number of people with chronic immune deficiencies. Key trends in the forecast period include advancements in plasma fractionation technology, the adoption of personalized medicine and targeted therapies, strategic partnerships between pharmaceutical companies and healthcare providers, ongoing clinical trials and studies to improve the efficacy of Bivigam, and the development of alternative immunoglobulin therapies to compete with bivigam.
The increasing prevalence of immunodeficiency disorders is expected to drive the growth of the bivigam market in the future. Immunodeficiency disorders are conditions where the immune system’s ability to defend against infections and diseases is weakened, which can result from genetic factors or external influences such as infections or treatments. Factors such as improved awareness and diagnosis, genetic predispositions, environmental changes, and the increased use of immunosuppressive therapies are contributing to the rise in these disorders. Bivigam, an intravenous immunoglobulin (IVIG) therapy, is used to treat primary immunodeficiency disorders by providing essential antibodies that help strengthen immune responses and prevent infections. For example, in July 2024, Immunodeficiency UK, a national patient organization in the UK, reported that over 450 distinct primary immunodeficiency (PID) conditions have been identified, with more than 5,000 individuals in the UK diagnosed with PID. As a result, the growing prevalence of immunodeficiency disorders is expected to boost the bivigam market.
The rise in healthcare expenditure is set to drive the growth of the bivigam market. The increase in healthcare spending is driven by advancements in medical technology, aging populations, the rising prevalence of chronic diseases, and the growing demand for quality care and personalized treatments. Increased investment in healthcare facilitates wider access to advanced treatments such as Bivigam, which is used for immune deficiency disorders. This trend is supported by the growing demand for innovative therapies and more investment in research on plasma fractionation technologies. For instance, according to a September 2024 report from the Centers for Medicare & Medicaid Services, U.S. healthcare spending increased by 4.1% in 2022, reaching $4.5 trillion, or $13,493 per person, which represents 17.3% of the nation’s GDP. Therefore, rising healthcare expenditure is expected to contribute to the growth of the bivigam market.
The increasing focus on personalized medicine is anticipated to accelerate the growth of the bivigam market. Personalized medicine is an approach that tailors healthcare decisions and treatments to an individual’s specific characteristics, needs, and genetic profile. The growing demand for personalized treatments is driven by advancements in genomics, targeted therapies, and the rising prevalence of chronic diseases, all of which require more precise and individualized treatment approaches. Personalized medicine enhances the effectiveness of Bivigam by adapting its intravenous immunoglobulin therapy to suit the unique needs of each patient, optimizing its efficacy in managing primary humoral immunodeficiency. For example, the Personalized Medicine Coalition, a U.S.-based non-profit organization, reported in February 2024 that the FDA approved 16 new personalized treatments for rare diseases in 2023, an increase from six in 2022. These treatments included seven cancer drugs and three for other diseases. Therefore, the growing focus on personalized medicine is expected to drive the bivigam market.
The key company operating in the bivigam market is ADMA Biologics Inc.
North America was the largest region in the bivigam market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in bivigam report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the bivigam market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Bivigam is an intravenous immune globulin (IVIG) therapy used to treat primary humoral immunodeficiency (PI), a group of disorders in which the immune system does not produce enough antibodies to fight infections. Derived from human plasma, it provides a broad range of antibodies to strengthen the immune response in PI patients.
The primary indications for bivigam include primary immunodeficiency, chronic immune thrombocytopenia (ITP), secondary immunodeficiency, neurological disorders, and other conditions. Primary immunodeficiency is a genetic disorder that impairs the immune system, making individuals more susceptible to infections, autoimmune diseases, and cancers. Bivigam is available in intravenous (IV) and subcutaneous (SC) formulations, with distribution through hospitals, specialty clinics, retail pharmacies, and online pharmacies. The drug is used by adult, pediatric, and geriatric patients.
The bivigam market research report is one of a series of new reports that provides bivigam market statistics, including bivigam industry global market size, regional shares, competitors with a bivigam market share, detailed bivigam market segments, market trends and opportunities, and any further data you may need to thrive in the bivigam industry. This bivigam market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The bivigam market consists of sales of intravenous immune globulin (IVIG) therapy products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historical period can be attributed to several factors, including the increasing prevalence of immune deficiency disorders, a rise in global healthcare spending, better access to life-saving treatments, greater awareness of immune deficiency disorders, regulatory approvals, and advancements in therapy guidelines.
Growth during the market's forecast period is expected to be driven by rising healthcare expenditure, growing demand for innovative immune therapies, expanded healthcare access in emerging markets, government and private funding for rare disease treatments, and an increasing number of people with chronic immune deficiencies. Key trends in the forecast period include advancements in plasma fractionation technology, the adoption of personalized medicine and targeted therapies, strategic partnerships between pharmaceutical companies and healthcare providers, ongoing clinical trials and studies to improve the efficacy of Bivigam, and the development of alternative immunoglobulin therapies to compete with bivigam.
The increasing prevalence of immunodeficiency disorders is expected to drive the growth of the bivigam market in the future. Immunodeficiency disorders are conditions where the immune system’s ability to defend against infections and diseases is weakened, which can result from genetic factors or external influences such as infections or treatments. Factors such as improved awareness and diagnosis, genetic predispositions, environmental changes, and the increased use of immunosuppressive therapies are contributing to the rise in these disorders. Bivigam, an intravenous immunoglobulin (IVIG) therapy, is used to treat primary immunodeficiency disorders by providing essential antibodies that help strengthen immune responses and prevent infections. For example, in July 2024, Immunodeficiency UK, a national patient organization in the UK, reported that over 450 distinct primary immunodeficiency (PID) conditions have been identified, with more than 5,000 individuals in the UK diagnosed with PID. As a result, the growing prevalence of immunodeficiency disorders is expected to boost the bivigam market.
The rise in healthcare expenditure is set to drive the growth of the bivigam market. The increase in healthcare spending is driven by advancements in medical technology, aging populations, the rising prevalence of chronic diseases, and the growing demand for quality care and personalized treatments. Increased investment in healthcare facilitates wider access to advanced treatments such as Bivigam, which is used for immune deficiency disorders. This trend is supported by the growing demand for innovative therapies and more investment in research on plasma fractionation technologies. For instance, according to a September 2024 report from the Centers for Medicare & Medicaid Services, U.S. healthcare spending increased by 4.1% in 2022, reaching $4.5 trillion, or $13,493 per person, which represents 17.3% of the nation’s GDP. Therefore, rising healthcare expenditure is expected to contribute to the growth of the bivigam market.
The increasing focus on personalized medicine is anticipated to accelerate the growth of the bivigam market. Personalized medicine is an approach that tailors healthcare decisions and treatments to an individual’s specific characteristics, needs, and genetic profile. The growing demand for personalized treatments is driven by advancements in genomics, targeted therapies, and the rising prevalence of chronic diseases, all of which require more precise and individualized treatment approaches. Personalized medicine enhances the effectiveness of Bivigam by adapting its intravenous immunoglobulin therapy to suit the unique needs of each patient, optimizing its efficacy in managing primary humoral immunodeficiency. For example, the Personalized Medicine Coalition, a U.S.-based non-profit organization, reported in February 2024 that the FDA approved 16 new personalized treatments for rare diseases in 2023, an increase from six in 2022. These treatments included seven cancer drugs and three for other diseases. Therefore, the growing focus on personalized medicine is expected to drive the bivigam market.
The key company operating in the bivigam market is ADMA Biologics Inc.
North America was the largest region in the bivigam market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in bivigam report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the bivigam market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Bivigam is an intravenous immune globulin (IVIG) therapy used to treat primary humoral immunodeficiency (PI), a group of disorders in which the immune system does not produce enough antibodies to fight infections. Derived from human plasma, it provides a broad range of antibodies to strengthen the immune response in PI patients.
The primary indications for bivigam include primary immunodeficiency, chronic immune thrombocytopenia (ITP), secondary immunodeficiency, neurological disorders, and other conditions. Primary immunodeficiency is a genetic disorder that impairs the immune system, making individuals more susceptible to infections, autoimmune diseases, and cancers. Bivigam is available in intravenous (IV) and subcutaneous (SC) formulations, with distribution through hospitals, specialty clinics, retail pharmacies, and online pharmacies. The drug is used by adult, pediatric, and geriatric patients.
The bivigam market research report is one of a series of new reports that provides bivigam market statistics, including bivigam industry global market size, regional shares, competitors with a bivigam market share, detailed bivigam market segments, market trends and opportunities, and any further data you may need to thrive in the bivigam industry. This bivigam market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The bivigam market consists of sales of intravenous immune globulin (IVIG) therapy products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Bivigam Market Characteristics4. Bivigam Market Trends and Strategies5. Bivigam Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Bivigam Pricing Analysis & Forecasts30. Global Bivigam Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Bivigam Market32. Recent Developments in the Bivigam Market
3. Bivigam Market Biologic Drug Characteristics
6. Global Bivigam Growth Analysis and Strategic Analysis Framework
8. Bivigam Market Segmentation
9. Global Bivigam Epidemiology of Clinical Indications
10. Bivigam Market Regional and Country Analysis
11. Asia-Pacific Bivigam Market
12. China Bivigam Market
13. India Bivigam Market
14. Japan Bivigam Market
15. Australia Bivigam Market
16. South Korea Bivigam Market
17. Western Europe Bivigam Market
18. UK Bivigam Market
19. Germany Bivigam Market
20. France Bivigam Market
21. Eastern Europe Bivigam Market
22. North America Bivigam Market
23. USA Bivigam Market
24. Canada Bivigam Market
25. South America Bivigam Market
26. Middle East Bivigam Market
27. Africa Bivigam Market
28. Bivigam Market Competitive Landscape and Company Profiles
29. Global Bivigam Market Pipeline Analysis
33. Bivigam Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Bivigam Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on bivigam market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for bivigam? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The bivigam market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Indication: Primary Immunodeficiency; Chronic Immune Thrombocytopenia (ITP); Secondary Immunodeficiency; Neurological Disorders; Other Indications2) by Formulation: Intravenous (IV) Solution; Subcutaneous (SC) Solution
3) by Distribution Channel: Hospitals; Specialty Clinics; Retail Pharmacies; Online Pharmacies
4) by End User: Adult; Pediatric; Geriatric
Key Companies Mentioned: ADMA Biologics Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- ADMA Biologics Inc.
